Skip to main content

DNAPrint Buys 18 Percent of Biofrontera for $1.8M, Expands Drug Pipeline

NEW YORK, July 14 (GenomeWeb News) - DNAPrint Genomics said yesterday that it had purchased an 18-percent share of Leverkusen, Germany-based Biofrontera for 1.5 million ($1.8 million), a prelude to the development of a new pharmaceutical pipeline for DNAPrint. 


DNAPrint said it will add two of Biofrontera's Phase II drugs to its stable for chronic uriticaria and actinic keratosis, called BF-Derm1 and 5-aminolevulonic acid, respectively, the company said. DNAPrint will also add "a series" of drugs that are in pre-clinical development, including a prophylactic migraine treatment, it said.


"The key goal of our pharmaceutical research is the development of test/drug combinations for helping to ensure efficacy with compatible patients," said Hector Gomez, DNAPrint's chief medical officer.


"Over the next several months we plan to expand our relationship with Biofrontera, especially in the drug development arena, and we plan to take advantage of each others' locations to help promote our respective products and services in each others' markets," said Richard Gabriel, president and CEO of DNAPrint.


Gabriel and Gomez will sit on the Biofrontera board of directors in connection with the transaction, the company said.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.